Walleye Capital
ESPR

Walleye Capital’s Esperion Therapeutics ESPR Stock Holding History

Walleye Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,900
Closed -$32.6K – 4858
2026
Q1 		$32.6K Sell
11,900
-147,800
-93% -$468K ﹤0.01% 3995
2025
Q4 		$591K Buy
159,700
+86,900
+119% +$281K ﹤0.01% 2852
2025
Q3 		$193K Buy
+72,800
New +$141K ﹤0.01% 3338
2025
Q1 		– Sell
-8,700
Closed -$19.1K – 4474
2024
Q4 		$19.1K Buy
+8,700
New +$20.3K ﹤0.01% 4508
2023
Q2 		– Sell
-6,300
Closed -$10K – 4463
2023
Q1 		$10K Buy
+6,300
New +$32.5K ﹤0.01% 3547
2022
Q4 		– Sell
-10,800
Closed -$72K – 3304
2022
Q3 		$72K Buy
+10,800
New +$74.2K ﹤0.01% 2515
2020
Q1 		– Sell
-29,200
Closed -$1.74M – 1146
2019
Q4 		$1.74M Sell
29,200
-27,300
-48% -$1.23M 0.11% 243
2019
Q3 		$2.07M Buy
56,500
+53,100
+1,562% +$2.1M 0.12% 212
2019
Q2 		$158K Sell
3,400
-11,000
-76% -$517K 0.02% 1056
2019
Q1 		$578K Buy
+14,400
New +$646K 0.1% 336

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Walleye Capital's ESPR Position: Q2 2026 in Review

Walleye Capital sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 3,031 shares — an estimated $8.3K sold.

Walleye Capital first reported a position in ESPR in Q2 2019 and held it in 13 quarters. The position peaked at $5.81M in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Walleye Capital reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 3,031 Esperion Therapeutics shares in Q2 2026, an estimated $8.3K.
  • Walleye Capital first reported a position in Esperion Therapeutics in Q2 2019 and held it in 13 quarters.
  • Walleye Capital's Esperion Therapeutics position peaked at $5.81M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.